Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy-Reference-Cited by-同舟云学术

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

Published:1996-01 Issue:2 Volume:35 Page:159-163
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Jørgensen Morten,Victor M. Alan

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/02841869609098496

Reference14 articles.

1. On the receiving end—patient perception of the side-effects of cancer chemotherapy

2. Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting

3. Intravenous metoclopramide: Prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation

4. Metoclopramide

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting;Journal of Pharmaceutical Health Care and Sciences;2018-01-09

2. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia;Current Problems in Cancer;2017-11

3. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP;Biological & Pharmaceutical Bulletin;2017

4. A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists;International Journal of Hematology;2016-06-16

5. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL);Supportive Care in Cancer;2010-08-08